№ lp_2_1_23053
File format: docx
Character count: 4842
File size: 25 KB
This document provides detailed clinical guidelines for the diagnosis, management, and genetic testing of Malignant Hyperthermia Susceptibility, based on molecular genetic testing of three specific genes.
Year:
2014
Region / City:
Seattle
Topic:
Medical Genetics
Document Type:
Clinical Guidelines
Organization / Institution:
University of Washington
Author:
Schneiderbanger D, Johannsen S, Roewer N, Schuster F
Target Audience:
Healthcare professionals, Anesthesiologists
Period of Validity:
Not specified
Date of Approval:
2014
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2020
Institution:
AmSECT
Document Type:
Clinical guideline
Target Population:
Patients with previously diagnosed risk or sudden onset of Malignant Hyperthermia
Purpose:
Guidance for detection, diagnosis, and management of Malignant Hyperthermia
Procedures Included:
Perfusion pump considerations, pharmacologic interventions, cooling strategies, laboratory testing
Approval:
Chief Medical Officer, Chief Nursing Executive
Effective Date:
2020
Version Number:
1.0
Review Period:
As changes occur or per institutional protocol
Year:
2026
Institution:
Gustave Roussy Cancer Center
Region:
France
Study type:
Clinical genomic study
Target population:
Patients with therapy-related myeloid neoplasms (TRMN) following breast or gynecologic cancers
Sample size:
77 patients
Methodology:
Targeted NGS panel of 74 genes
Data type:
Mutation profiles, comutation plots, survival analyses
Classification systems:
ELN 2017 for AML, IPSS for MDS
Follow-up:
Overall survival according to malignancy type, mutations, and treatment received
Figures and tables:
Comutation plot, OS plots, mutation frequency tables
Year:
2026
Institution:
Rice University, MD Anderson Cancer Center, NuProbe USA
Department:
Bioengineering; Systems, Synthetic, and Physical Biology; Leukemia; Translational Molecular Pathology
Authors:
Peng Dai, Lucia Ruojia Wu, Sherry Xi Chen, Michael Xiangjiang Wang, Lauren Yuxuan Cheng, Jinny Xuemeng Zhang, Christina Pengying Hao, Weijie Yao, Jabra Zarka, Ghayas C. Issa, Lawrence Kwong, David Yu Zhang
Type:
Supplementary Material
Subject:
NGS quantitation, mutation detection, QBDA method, leukemia and tuberculosis panels
Target Audience:
Researchers in genomics and molecular diagnostics
Techniques:
Single-plex and multiplex QBDA, spike-in reference standards, LoD determination, sequencing depth analysis
Reference Standards:
Myeloid DNA Reference Standard, NA18562 genomic DNA, synthetic gBlocks
Mutation Frequency Range:
0.01%–70% VAF
Data:
Primer sequences and SNP/mutation panels provided in supplementary tables and spreadsheet files
Document type:
Research project consultation form
Research field:
Genomics / Next-Generation Sequencing
Purpose:
Collection of project information for NGS sequencing and analysis planning
Sections:
Researcher section; NGS Core facility section
Information requested from researcher:
Project title; Reference number or research network affiliation; Applicant institution contact; Research field; Project summary; NGS applications; Sample type and number; Sample delivery schedule; Bioinformatics support requirements
Information completed by facility:
Internal project ID; Library preparation protocols; Sample input limitations; Sequencer platform; Data output per sample; Study design with controls or replicates; Comments on experimental design; Comments on experiments; Library preparation costs; Sequencing costs; Data analysis comments
Organizations involved:
Applicant research institution; NGS Core facility
Related technologies:
Next-Generation Sequencing (NGS); RNA sequencing; ATAC sequencing; single-cell RNA sequencing
Sample types mentioned:
Cells; Chromatin; DNA; RNA
Administrative fields:
Date of consultation; Applicant signature; NGS Core signature
Year:
2015
Region / City:
United States
Subject:
Antimicrobial Susceptibility Testing
Document Type:
Template
Organization:
Regional Medical Center
Author:
N/A
Target Audience:
Laboratory personnel involved in AST testing
Effective Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Date:
21/02/2025
Reference number:
EMA/457563/2023
Department:
Therapeutic Areas Department
Subject:
Antimicrobial susceptibility testing
Type of document:
Regulatory text for SmPC
Issuing body:
European Medicines Agency
Responsible committee:
European Committee on Antimicrobial Susceptibility Testing (EUCAST)
Related substance:
{INN}
Applicable section:
SmPC Section 5.1
Language versions:
Multiple EU languages
Source link:
https://www.ema.europa.eu/documents/other/minimum-inhibitory-concentration-mic-breakpoints_en.xlsx
Note:
Year
Topic:
Antimicrobial Susceptibility Testing
Document Type:
Standard Operating Procedure
Context:
Standard operating procedure for antimicrobial susceptibility testing using Etest for determining MIC values of pathogenic bacteria.
Year:
2020
Region / city:
Indore, Madhya Pradesh
Topic:
Antimicrobial resistance
Document type:
Research article
Organization / institution:
M.G.M. Medical College, Indore
Author:
Bharat Singh, Neeraj Kumar Bagde, Ranjana Dahariya, Anita Mutha
Target audience:
Medical professionals, researchers, healthcare providers
Period of validity:
July 2018 - July 2019
Approval date:
Not mentioned
Date of revisions:
Not mentioned
Year:
Not specified
Region / City:
Not specified
Topic:
Diabetes, fungal infections, metformin, PTP1B inhibitors, Candida albicans
Document Type:
Research Project Report
Author:
Not specified
Target Audience:
Researchers, medical professionals
Duration:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Procedure ID:
PSAv1.0
Version number:
1.0
Release date:
20 March 2017
Developed by:
Benoit Witkowski & Didier Ménard
Institution:
Unité d’Epidémiologie Moléculaire du Paludisme, Institut Pasteur du Cambodge
Location:
Phnom Penh, Cambodia
Document type:
Laboratory procedure
Purpose:
Evaluation of Plasmodium falciparum susceptibility to piperaquine
Assay types:
In-vitro Piperaquine Survival Assay (PSA); Ex-vivo Piperaquine Survival Assay
Target organism:
Plasmodium falciparum
Drug tested:
Piperaquine (PPQ)
Drug concentration:
200 nM
Exposure duration:
48 hours
Assessment time point:
72 hours after drug exposure
Intended users:
Appropriately-equipped laboratories performing in-vitro and ex-vivo drug susceptibility testing
Quality requirements:
Training required; participation in QA/QC proficiency scheme recommended
Referenced study:
Duru et al. 2015
Contact information:
[email protected]
Year:
2021
Region / City:
Zhejiang Province, China
Topic:
Epilepsy, Neuroscience
Document Type:
Research Article
Organization / Institution:
Zhejiang University
Author:
Lin Zhou, Liang Zhou, Li-Da Su, Sheng-Long Cao, Ya-Jun Xie, Ying Shen
Target Audience:
Researchers in neuroscience and epilepsy
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
Not specified
Region / city:
Not specified
Theme:
Breast cancer genetics
Document type:
Research figure
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers, oncologists
Action period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Context:
A research document presenting the association analysis between YTHDC1 SNPs and breast cancer susceptibility, including figures for SNP analysis and m6A modification prediction.
Year:
2025
Institution / Location:
Enugu State University of Science and Technology, Enugu, Nigeria
Department:
Microbiology
Study Design:
Descriptive cross-sectional
Sample Size:
150 students
Specimens Collected:
Ear swabs
Bacterial Species Identified:
Escherichia coli, Pseudomonas spp, Klebsiella spp, Streptococcus spp, Staphylococcus aureus
Antibiotic Resistance:
Multidrug resistance observed
Methodology:
Culture techniques and Kirby-Bauer susceptibility testing according to CLSI guidelines
Duration:
June to August 2025
Target Population:
Apparently healthy university students
Health Implications:
Potential public health risk due to asymptomatic colonization